CRP and myocardial infarction: Recently, CRP apheresis has been suggested as an alternative translational therapy to reduce CRP levels and tissue damage, using a phosphocholine-derivative matrix as a ligand for CRP, which could be useful to selectively deplete CRP from blood plasma in patients recovering from acute myocardial infarction [9], and other inflammatory conditions such as SLE.